A Phase I, Open-label, Excretion Balance, Pharmacokinetic and Metabolism Stud After Single Oral Dose of 14C-labeled RO5185426 in Previously Treated and Untreated Patients With Metastatic Melanoma

Trial Profile

A Phase I, Open-label, Excretion Balance, Pharmacokinetic and Metabolism Stud After Single Oral Dose of 14C-labeled RO5185426 in Previously Treated and Untreated Patients With Metastatic Melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Sep 2012 Planned end date changed from 1 Jul 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 15 Mar 2011 Planned end date changed from 1 Apr 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top